



summit<sub>plc</sub>

**Summit Corporation plc**  
**(“Summit” or “the Company”)**

**NOTICE OF ANNUAL GENERAL MEETING**

**Oxford, UK, 29 July 2009** – Summit Corporation plc (AIM: SUMM), a UK drug discovery company, announces that its Annual Report and Accounts for the year ended 31 January 2009 ('Annual Report') together with the Notice of Annual General Meeting ('AGM') and Proposed Capital Reorganisation have been posted to shareholders. Copies of the Annual Report will also be available on the Company's website, [www.summitplc.com](http://www.summitplc.com).

The AGM will be held at the Company's registered office, 91 Milton Park, Abingdon, Oxfordshire, OX14 4RY, on Thursday, 20 August 2009 at 10am.

- ENDS -

**For more information, please contact:**

**Summit plc**

Steven Lee, PhD

Richard Pye, PhD

Tel: +44 (0)1235 443951

**Panmure Gordon**

Andrew Burnett / Rakesh Sharma (Corporate Finance)

Ashton Clanfield (Corporate Broking)

Tel: +44 (0)207 459 3600



summit<sub>plc</sub>

## About Summit plc

Summit plc is a UK based drug discovery company with a major focus on developing new therapeutics from its iminosugar drug discovery platform.

Summit believes iminosugars are the key to gaining access to several disease mechanisms where classical drugs have had little success, and thus offer a major opportunity for the discovery and development of new medicines.

Carbohydrates (sugars) play critical roles in maintaining correct functioning of many normal processes in healthy individuals and errors in carbohydrate recognition or modification can lead to malfunction in cells resulting in disease. Iminosugars have the potential to mimic carbohydrates or to interact with processes which manipulate carbohydrates to modify activity or to correct aberrant function. Additionally, the structural features of iminosugars allow them to have important effects when interacting with many other unexploited therapeutic targets.

Commercially, Summit has a track record of signing programme agreements and currently has an out-licensed product portfolio comprising of four drug programmes with BioMarin, Orient Europharma, Evolva and the Lilly TB Drug Discovery Initiative. In the future these programmes may generate success based milestone payments and royalties for Summit.

In addition, Summit owns Dextra Laboratories, a business unit that operates independently to Summit, which offers specialist carbohydrate chemistry services to third parties on a fee-for-service or collaborative basis.

The company listed on the alternative investment market (AIM) of the London Stock Exchange in October 2004 - symbol: SUMM. Further information about the company is available at [www.summitplc.com](http://www.summitplc.com).

*This document contains "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as "anticipates", "intends", "plans", "seeks", "believes", "estimates", "expects" and similar references to future periods, or by the inclusion of forecasts or projections.*

*Forward-looking statements are based on the Company's current expectations and assumptions regarding our business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. The Company's actual results may differ materially from those contemplated by the forward-looking statements. The Company cautions you therefore that you should not rely on any of these forward-looking statements as statements of historical fact or as guarantees or assurances of future performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements and regional, national, global political, economic, business, competitive, market and regulatory conditions.*